In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumours with a cell-penetrating anti-DNA autoantibody.

The study was published today online in the Journal of Clinical Investigation Insight.

"These findings are very encouraging as the BBB prevents most antibodies from penetrating the central nervous system and limits conventional antibody-based approaches to brain tumours," said James E. Hansen, MD, associate professor of therapeutic radiology, radiation oncology chief of the Yale Gamma Knife Center at Smilow Cancer Hospital, and corresponding author of the study.

Deoxymab-1 (DX1) is an unusual cell-penetrating autoantibody that localises into live cell nuclei, inhibits DNA repair, and is synthetically lethal to cancer cells with defects in the DNA damage response (DDR).

Researchers have now found that the transporter ENT2 facilitates brain endothelial cell penetration and BBB transport by DX1.

In efficacy studies in mice models, DX1 crossed the BBB to suppress orthotopic glioblastoma and breast cancer brain metastases.

"Our data demonstrate the ability of DX1 to cross the BBB and suppress brain tumours in multiple models, and we are particularly impressed that DX1 was able to yield these results as a single agent in these difficult to treat tumour models," said Jiangbing Zhou, associate professor of neurosurgery at Yale School of Medicine and co-corresponding author of the study.

"We believe that the ENT2-linked mechanism that transports DX1 across the BBB and into tumours has potential to contribute to multiple new strategies in brain tumour therapy," added Hansen. "In addition to establishing proof of concept for single agent use of DX1 in brain tumour models, we also now recognise the potential for DX1 to target linked cargo molecules to brain tumours or to be useful as a platform for designing additional brain tumour targeting antibodies, including DX1-based bispecific antibodies."

Source: Yale University